Zealand Pharma A/S (OTCMKTS:ZLDPF) Given Average Rating of “Strong Buy” by Brokerages

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have been given a consensus rating of “Strong Buy” by the eight brokerages that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and six have assigned a strong buy recommendation to the company.

ZLDPF has been the topic of a number of recent analyst reports. BTIG Research upgraded Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Zealand Pharma A/S in a research note on Tuesday, December 16th.

Zealand Pharma A/S Price Performance

Shares of ZLDPF stock opened at $65.28 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.10 and a quick ratio of 14.10. The company has a market capitalization of $4.64 billion, a PE ratio of 4.70 and a beta of 0.74. The firm’s 50-day moving average is $75.52 and its two-hundred day moving average is $69.07. Zealand Pharma A/S has a 12 month low of $49.98 and a 12 month high of $110.00.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.21. The business had revenue of $7.76 million during the quarter, compared to analysts’ expectations of $4.54 million. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. Analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.